Sanofi SA, in collaboration with Regeneron Pharmaceuticals, Inc., has announced the results of the EVEREST phase 4 clinical study involving Dupixent (dupilumab) for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. The study demonstrated that Dupixent outperformed Xolair (omalizumab) across all primary and secondary efficacy endpoints related to CRSwNP and asthma. Key findings included a 1.60-point reduction in nasal polyp size and an 8.0-point improvement in the ability to identify different smells. These results were presented at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Glasgow, UK. The study involved 360 adult participants and highlighted Dupixent's efficacy in targeting IL-4 and IL-13, significant drivers of type 2 inflammation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.